<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04218851</url>
  </required_header>
  <id_info>
    <org_study_id>5592-104</org_study_id>
    <secondary_id>2019-002267-10</secondary_id>
    <secondary_id>MK-5592-104</secondary_id>
    <nct_id>NCT04218851</nct_id>
  </id_info>
  <brief_title>Posaconazole (MK-5592) Intravenous and Oral in Children With Invasive Aspergillosis (IA) (MK-5592-104)</brief_title>
  <official_title>A Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole (POS, MK-5592) in Pediatric Participants Aged 2 to &lt;18 Years With Invasive Aspergillosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, efficacy, and pharmacokinetics of posaconazole (POS)
      intravenous (IV) and oral formulations in pediatric participants 2 to &lt;18 years of age with
      invasive aspergillosis (IA).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 2, 2020</start_date>
  <completion_date type="Anticipated">February 6, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 6, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participants with Treatment Related Adverse Events (AEs)</measure>
    <time_frame>Up to 14 days after treatment (up to Day 100)</time_frame>
    <description>Percentage of participants who experience one or more treatment-related adverse events (AEs)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Participants with a favorable global clinical response</measure>
    <time_frame>Up to End of Trial (EOT) visit (up to Day 87)</time_frame>
    <description>Percentage of participants who have a favorable global clinical response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants who have a relapse of invasive aspergillosis (IA)</measure>
    <time_frame>Up to 28 days post-treatment (up to Day 114)</time_frame>
    <description>Percentage of participants who have a relapse of invasive aspergillosis (IA) at any point after achieving favorable global clinical response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average plasma concentration (Cavg) of Posaconazole (POS)</measure>
    <time_frame>Pre-dose, Day 1, Weeks 1, 2, 4, 6, 9 and 12</time_frame>
    <description>Average plasma concentration (Cavg) of Posaconazole (POS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum plasma concentration (Cmin) of POS</measure>
    <time_frame>Pre-dose, Day 1, Weeks 1, 2, 4, 6, 9 and 12</time_frame>
    <description>Minimum plasma concentration (Cmin) of POS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax) of POS</measure>
    <time_frame>Pre-dose, Day 1, Weeks 1, 2, 4, 6, 9 and 12</time_frame>
    <description>Maximum plasma concentration (Cmax) of POS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve (AUC) of POS</measure>
    <time_frame>Pre-dose, Day 1, Weeks 1, 2, 4, 6, 9 and 12</time_frame>
    <description>Area under the concentration-time curve (AUC) of POS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach Cmax (Tmax) of POS</measure>
    <time_frame>Pre-dose, Day 1, Weeks 1, 2, 4, 6, 9 and 12</time_frame>
    <description>Time to reach Cmax (Tmax) of POS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants with different categories of palatability</measure>
    <time_frame>Day 8 and Day 84</time_frame>
    <description>Percentage of participants with different categories of palatability after treatment with the POS PFS formulation</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Invasive Aspergillosis</condition>
  <arm_group>
    <arm_group_label>Posaconazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On Day 1 participants will receive two treatments of Posaconazole (POS)) 6 mg/kg body weight by intravenous (IV) infusion; on Days 2 through 7 participants will receive POS 6 mg/kg body weight once daily by IV infusion; beginning at Day 8 up to Day 84, participants may transition to receiving an oral formulation, or they may remain on an IV formulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Posaconazole IV</intervention_name>
    <description>Posaconazole (POS) 6 mg/kg body weight by IV infusion</description>
    <arm_group_label>Posaconazole</arm_group_label>
    <other_name>MK-5592</other_name>
    <other_name>SCH 056592</other_name>
    <other_name>Noxafil®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Posaconazole PFS</intervention_name>
    <description>POS PFS 6 mg/kg body weight taken orally</description>
    <arm_group_label>Posaconazole</arm_group_label>
    <other_name>MK-5592</other_name>
    <other_name>SCH 056592</other_name>
    <other_name>Noxafil®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Posaconazole tablet</intervention_name>
    <description>POS tablet 300 mg taken orally</description>
    <arm_group_label>Posaconazole</arm_group_label>
    <other_name>MK-5592</other_name>
    <other_name>SCH 056592</other_name>
    <other_name>Noxafil®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has a diagnosis of possible, probable, or proven IA per modified 2008 European
             Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG)
             disease definitions

          -  Has one or more of pre-defined risks as per modified 2008 EORTC/MSG disease
             definitions

          -  Meets pre-defined mycologic and clinical criteria as per modified 2008 EORTC/MSG
             disease definitions

          -  Has demonstrated fungal elements (by cytology or microscopy) or positive culture for
             Aspergillus obtained by sterile sampling of disease tissue as per modified EORTC/MSG
             disease definitions

          -  Has a central line (e.g., central venous catheter, peripherally-inserted central
             catheter) in place or planned to be in place prior to beginning IV study treatment.

          -  Has clinical symptoms consistent with an acute episode of IA, defined as duration of
             clinical syndrome of &lt;30 days.

          -  During the intervention period and for at least 30 days after the last dose of study
             treatment, males agree to be abstinent from heterosexual intercourse or use
             contraception unless confirmed to be azoospermic (vasectomized or secondary to medical
             cause).

          -  Female is is not pregnant or breastfeeding, and is not a woman of child bearing
             potential (WOCBP) or is a WOCBP using a highly effective contraceptive method. A WOCBP
             must have a negative highly sensitive pregnancy test (urine or serum as required by
             local regulations) within 24 hours before the first dose of study intervention.

        Exclusion Criteria:

          -  Has chronic (≥30 days' duration) IA, relapsed/recurrent IA, or refractory IA that has
             not responded to prior antifungal treatment.

          -  Has cystic fibrosis, pulmonary sarcoidosis, aspergilloma, or allergic bronchopulmonary
             aspergillosis.

          -  Has a known hypersensitivity or other serious adverse reaction to any azole antifungal
             therapy, or to any other ingredient of the study treatment used.

          -  Has any known history of torsade de pointes, unstable cardiac arrhythmia or
             proarrhythmic conditions, a history of recent myocardial infarction, congenital or
             acquired QT prolongation, or cardiomyopathy in the context of cardiac failure within
             90 days of time of first dose of study treatment.

          -  Has a known hereditary problem of galactose intolerance, Lapp lactase deficiency, or
             glucose-galactose malabsorption.

          -  Is on artificial ventilation or receiving acute continuous positive airway pressure
             (CPAP)/bilevel positive airway pressure (BPAP) at the time of first dose of study
             treatment.

          -  Has known or suspected Gilbert's disease.

          -  A WOCBP who has a positive urine pregnancy test within 72 hours before the first dose
             of study intervention or at any time during the study.

          -  Has received any treatment prohibited by the protocol.

          -  Has enrolled previously in the current study and been discontinued.

          -  Is not expected, in the opinion of the investigator, to survive for at least 1 month
             after the initiation of study treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>General Hospital of Thessaloniki &quot;Ippokrateio&quot; ( Site 1050)</name>
      <address>
        <city>Thessaloniki</city>
        <zip>546 42</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+302313312444</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital ( Site 1326)</name>
      <address>
        <city>Seoul</city>
        <state>Seoul-teukbyeolsi [Seoul]</state>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>82220723452</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea. Seoul St. Mary s Hospital ( Site 1325)</name>
      <address>
        <city>Seoul</city>
        <state>Seoul-teukbyeolsi [Seoul]</state>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>82222586188</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Enfermedades Neoplásicas ( Site 1251)</name>
      <address>
        <city>Lima</city>
        <zip>15038</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+51993536178</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dmitry Rogachev National Research Center ( Site 1275)</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>117198</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79161666692</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute of Child Hematology and Transpl n.a.R.M.Gorbacheva ( Site 1281)</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Sankt-Peterburg</state>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+78122337006</phone>
    </contact>
  </location>
  <location_countries>
    <country>Greece</country>
    <country>Korea, Republic of</country>
    <country>Peru</country>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 3, 2020</study_first_submitted>
  <study_first_submitted_qc>January 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 6, 2020</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspergillosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Posaconazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

